ArticleCureus2026
Evaluation of Acute Pancreatitis in Patients Receiving Doxycycline Therapy: A Prospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Acute pancreatitis is an inflammatory disorder of the pancreas with diverse etiologies, among which drug-induced pancreatitis (DIP) represents a rare but clinically important subset. Doxycycline, a widely used tetracycline antibiotic, has been infrequently implicated as a causative agent in isolated case reports, leaving the true incidence and risk factors unclear. Objective This prospective study aimed to evaluate the incidence, clinical characteristics, and biochemical profile of acute pancreatitis in patients receiving doxycycline therapy and to identify potential associations between patient characteristics, duration of therapy, and disease occurrence. Methods This 24-month prospective observational study was conducted at Khyber Teaching Hospital, Peshawar, Pakistan. A total of 130 adult patients receiving doxycycline therapy were enrolled, of whom 124 completed follow-ups. Baseline pancreatic, hepatic, and renal enzyme profiles were assessed before therapy initiation, and patients were followed weekly for clinical symptoms and biochemical parameters. Acute pancreatitis was diagnosed according to the revised Atlanta criteria. Data were analyzed using IBM SPSS Statistics for Windows, Version 26 (Released 2018; IBM Corp., Armonk, New York, United States). Quantitative variables were expressed as mean ± SD, and categorical variables as n (%). Associations were evaluated using chi-square and t-tests, with p < 0.05 considered statistically significant. Results Among 124 participants, seven patients (5.6%) developed acute pancreatitis confirmed by biochemical and radiological findings. The mean latency to onset was 8.1 ± 2.3 days. The mean duration of therapy was significantly longer in affected patients (12.3 ± 2.1 vs. 10.6 ± 3.1 days; p = 0.03), while no significant associations were observed with age, gender, or BMI. All affected patients presented with classical symptoms, elevated serum amylase (422 ± 118 U/L) and lipase (698 ± 210 U/L), and recovered completely with conservative management. No mortality occurred. Conclusion Doxycycline-induced acute pancreatitis, though uncommon, is a clinically relevant adverse event with favorable outcomes upon early detection and drug withdrawal. Prolonged therapy beyond 10 days may increase risk, underscoring the need for clinical vigilance and patient monitoring during treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.